23andMe to offer genetic reports on diabetes

pharmafile | March 11, 2019 | News story | Sales and Marketing 23andME, Genentech, GlaxoSmithKline, Lundbeck, diabetes, genetics, genomics 

Personal genomics company, 23andMe will offer customers information on the likelihood that they are genetically predisposed to developing type 2 diabetes.

The company, whose partners include pharmaceutical firm’s Genentech, Lundbeck and GlaxoSmithKline, has genotyped more than 3,000,000 individuals and has one of the largest collections of genomic data in the world.

“Diabetes is a significant health issue in the United States that is expected to impact nearly half of the population. When customers learn about their genetic likelihood of developing type 2 diabetes, we believe there is an opportunity to motivate them to change their lifestyle and ultimately to help them prevent the disease,” said Anne Wojcicki, CEO and Co-Founder of 23andMe.  

Reports will be available to all existing customers as well as any new customers willing to share their saliva and pay $199.

While the FDA has previously authorised 23andMe to sell risk assessment tests for among other conditions, breast cancer, Alzheimer’s and Parkinson’s, the diabetes test did not require FDA approval, instead falling under the guidance for wellness products.

The reports will be linked to a service provided by 23andMe partner Lark Health which offers a chatbot coaching service for patients with a predisposition to diabetes.

Louis Goss

Related Content

Genentech shares positive results from phase 3 trial for breast cancer treatment

Genentech, a member of the Roche Group, has announced positive results from the phase 3 …

Roche to acquire Carmot Therapeutics for $2.7bn

Roche has announced that it has entered into a definitive merger agreement with Carmot Therapeutics, …


Genentech and NVIDIA enter AI research collaboration

Genentech has announced that it has entered into a multi-year strategic research collaboration with NVIDIA …

Latest content